A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. by Laura M Walker, Melissa D Simek, Frances Priddy, Johannes S Gach, Denise Wagner, Michael B Zwick, Sanjay K Phogat, Pascal Poignard, Dennis R Burton

Get full text

Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trialsResearch in context by Christopher L. Cooper, Gavin Morrow, Maoli Yuan, Thomas S. Postler, Maxwell L. Neal, Robert W. Cross, Courtney Woolsey, Krystle N. Agans, Viktoriya Borisevich, Ryan P. McNamara, Caroline Atyeo, Vicky Roy, Daritza Germosen, Fuxiang Hou, Shui L. Li, Lucia Reiserova, Yesle Choi, Aaron Wilson, Denise Wagner, Olivia Wallace-Selman, Alexei Carpov, Fuqiang Geng, Deborah J. Frederick, Joanne DeStefano, Anne M. Ercolini, Adrian S. Enriquez, Kathryn M. Hastie, Suzane Ramos da Silva, Eddy Sayeed, John W. Coleman, Andrew Kilianski, Galit Alter, Erica Ollmann Saphire, John D. Aitchison, Thomas W. Geisbert, Swati B. Gupta, Mark B. Feinberg, Christopher L. Parks

Get full text